184 related articles for article (PubMed ID: 32274748)
1. Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy.
Ni Y; Qin Y; Huang Z; Liu F; Zhang S; Zhang Z
Adv Ther; 2020 May; 37(5):2550-2559. PubMed ID: 32274748
[TBL] [Abstract][Full Text] [Related]
2. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
3. Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Kaarniranta K; Resch MD
BMC Ophthalmol; 2020 Dec; 20(1):491. PubMed ID: 33371882
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 2000 May; 129(5):678-80. PubMed ID: 10844070
[TBL] [Abstract][Full Text] [Related]
5. Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study.
Begum G; O'Neill J; Chaudhary R; Blachford K; Snead DRJ; Berry M; Scott RAH; Logan A; Blanch RJ
Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):4929-4936. PubMed ID: 30347087
[TBL] [Abstract][Full Text] [Related]
6. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
Kon CH; Occleston NL; Aylward GW; Khaw PT
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
[TBL] [Abstract][Full Text] [Related]
7. Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Resch MD
PLoS One; 2020; 15(6):e0234525. PubMed ID: 32542038
[TBL] [Abstract][Full Text] [Related]
8. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
9. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
10. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Yamamoto S; Yamamoto T; Tsukahara I; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Jpn J Ophthalmol; 2002; 46(2):218-21. PubMed ID: 12062231
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis in proliferative vitreoretinopathy.
El Ghrably I; Powe DG; Orr G; Fischer D; McIntosh R; Dua HS; Tighe PJ
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1473-9. PubMed ID: 15111604
[TBL] [Abstract][Full Text] [Related]
12. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518
[TBL] [Abstract][Full Text] [Related]
15. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.
El-Ghrably IA; Dua HS; Orr GM; Fischer D; Tighe PJ
Br J Ophthalmol; 2001 Apr; 85(4):461-70. PubMed ID: 11264138
[TBL] [Abstract][Full Text] [Related]
17. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
18. Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.
Symeonidis C; Androudi S; Georgalas I; Tzamalis A; Chalvatzis N; Rotsos T; Souliou E; Diza E; Dimitrakos SA
Clin Exp Immunol; 2015 Aug; 181(2):338-42. PubMed ID: 25766782
[TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
20. Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.
Kenarova B; Voinov L; Apostolov C; Vladimirova R; Misheva A
Eur J Ophthalmol; 1997; 7(1):64-7. PubMed ID: 9101198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
